Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes

ISSN： 0741-238X

Source： Advances in Therapy, Vol.31, Iss.3, 2014-03, pp. : 247-263

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m 2 in Spain

By Fonseca Tiago

Journal of Medical Economics, Vol. 16, Iss. 7, 2013-07 ,pp. : 926-938

Informa Healthcare

Access to resources Recommend Favorite

Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 71, Iss. 12, 2017-12 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

All‐cause and diabetes‐related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 672-680

John Wiley & Sons Inc

Access to resources Recommend Favorite

Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide

By Schwartz Stanley

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3009-3022

Informa Healthcare

Access to resources Recommend Favorite

Dulaglutide: a once‐weekly GLP‐1 for type 2 diabetes

PRESCRIBER, Vol. 26, Iss. 19, 2015-10 ,pp. : 28-30

John Wiley & Sons Inc

Access to resources Recommend Favorite